Zevra Therapeutics reported Q2 2026 net revenue of $39.7M, up 53% from $25.9M year over year, with growth driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA. The strong top-line growth is a positive near-term signal for commercial traction.
Zevra Therapeutics reported Q2 2026 net revenue of $39.7M, up 53% from $25.9M year over year, with growth driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA. The strong top-line growth is a positive near-term signal for commercial traction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
